Tejiokem M. C., Desselas Emilie, Noumsi T. J., Ndongo F. A., Ndiang S. T., Fossi M. A., Guemkam G., Tekougang B. Z. K., Tagnouokam-Ngoupo P. A., Penda I. C., Faye A., Warszawski J. (2025). Pre- and post-vaccination measles antibody and persistence up to 5 years of age among early ART-treated HIV-infected, HIV-exposed Uninfected and HIV-unexposed children in Cameroon. Vaccines, 13 (6), p. 584 [16 p.].
Titre du document
Pre- and post-vaccination measles antibody and persistence up to 5 years of age among early ART-treated HIV-infected, HIV-exposed Uninfected and HIV-unexposed children in Cameroon
Année de publication
2025
Auteurs
Tejiokem M. C., Desselas Emilie, Noumsi T. J., Ndongo F. A., Ndiang S. T., Fossi M. A., Guemkam G., Tekougang B. Z. K., Tagnouokam-Ngoupo P. A., Penda I. C., Faye A., Warszawski J.
Source
Vaccines, 2025,
13 (6), p. 584 [16 p.]
Background/Objective: Variations in measles vaccine antibody response by age and HIV status have been reported. This study assessed measles pre-vaccination status and compared humoral response durability over the first five years of life among HIV-infected (HI) children on early treatment, HIV-exposed uninfected (HEU), and HIV-unexposed uninfected (HUU) children within the ANRS 12225-Pediacam III cohort in Cameroon. Methods: Measles vaccine (MCV) was administered at 6 and 9 months for HIV-exposed infants and at 9 months for HIV-unexposed infants, followed by a measles-mumps-rubella (MMR) dose at 15 months for all. Measles antibody titers were measured pre-vaccination, 1-6 months post-MCV doses, and annually until age 5 using ELISA (Enzygnost, Dade Behring). Results: A total of 496 children were included: 143 HI (median age at cART initiation: 4.2 months, (IQR: 3.2-5.6)), 180 HEU, and 173 HUU. Of these, 456 children were tested pre-vaccination (median age: 6.1 months, IQR: 5.6-6.8), with 6.1% (95% CI: 4.1-8.6) seropositive to measles antibodies, with differences across groups. At 18.4 months (IQR: 18.1-19.9), seropositivity rates were 96.7% (59/61) in HI, 96.8% (90/93) in HEU, and 100% (111/111) in HUU groups. For children following the 6 + 9 + 15-month or 9 + 15-month MCV schedules, seropositivity at 18, 36, 48, and 60 months was 96%, 89%, 87%, and 88%, respectively, with no significant differences between groups. Conclusions: Early cART initiation in HI children may result in a robust initial measles antibody response, with comparable persistence of antibody titers across all groups up to five years.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
CAMEROUN
Localisation
Fonds IRD [F B010094237]
Identifiant IRD
fdi:010094237
